Tradestie Institutional Equity Comparison Engine

ABUS vs YQQQ โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus YQQQ at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABUS sits in CONSOLIDATION (28th %ile IV; Dealer Gamma Walls on Pro) against YQQQ sits in UNCLASSIFIED (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABUS
ABUS 10.2x vs YQQQ N/M Fwd P/E
Growth & Margin Winner ABUS
Op Margin 80.1% vs N/A ยท YoY -43.5% vs N/A
Momentum & Technical Winner ABUS
1Y -11.4% vs -20.6% ยท 52W Pos 28% vs 17%
Options & Structure Winner ABUS
CONSOLIDATION (28th %ile IV) vs UNCLASSIFIED (13th %ile IV)
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap $627.0M
1M Return -4.27%
1Y Return -11.4%
Forward P/E 10.2x
Unified AI Score
56.7 / 100 HOLD
Tech 73.0 Fund 66.0 Flow 68.0 Mom 53.7
YQQQ NASDAQ
YieldMax Short N100 Option Income Strategy ETF
Institutional Equity
$9.84
+2.1% 1D
Market Cap N/A
1M Return +2.59%
1Y Return -20.65%
Forward P/E N/M
Unified AI Score
50.6 / 100 HOLD
Tech 58.0 Fund 55.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABUS -11.4% YQQQ -20.65% Spread: +9.25 pp (ABUS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABUS TTM Op. Margin: 80.1% YQQQ TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs YQQQ. Trailing 12-month operating profitability (ABUS 80.1% vs YQQQ N/A) and valuation multiples (ABUS 10.2x vs YQQQ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABUS (9) vs YQQQ (1)
Institutional Metric ABUS YQQQ Criterion Row Winner
Market Capitalization Scale $627.0M N/A Larger Scale ABUS
Trailing P/E Ratio Valuation 3.6x N/M Lower Multiple ABUS
Forward P/E Ratio Valuation 10.2x N/M Lower Multiple ABUS
Revenue Growth (YoY) Growth -43.5% N/A Higher Growth ABUS
Operating Margin (TTM) Profitability 80.1% N/A Higher Margin ABUS
Net Profit Margin Profitability 121.2% N/A Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency 269.6% N/A Higher ROE ABUS
52-Week Range Position Momentum 28% ($4โ€“$5) 17% ($9โ€“$13) Stronger Trend ABUS
Beta / 30D Volatility Risk Regime 1.20ฮฒ ยท 51% Vol -1.10ฮฒ ยท 27% Vol Lower Realized Risk YQQQ
Unified Institutional Score Composite Signal 56.7 / 100 (HOLD) 50.6 / 100 (HOLD) Higher Composite ABUS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABUS vs YQQQ Buy Guide
ABUS CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 28th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
YQQQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live YQQQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABUS nor YQQQ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.